A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia

Dermatol Ther. 2020 Jul;33(4):e13734. doi: 10.1111/dth.13734. Epub 2020 Jul 13.


Αndrogenetic alopecia (AGA) is the most common hair disorder, affecting approximately 50% of men and women. A topical lotion that contains two patented formulas (Redensyl and Sepicontrol A5), has been introduced as an alternative approach to standard therapies for AGA. Forty-four patients with AGA were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (anagen-to-telogen ratio). Forty-one patients, 18 males and 23 females, completed the study. Among patients receiving active treatment (n = 26), 7.7% had great improvement, 73.1% had moderate improvement, and 19.2% remained stable. The median self-assessment score increased from 4 at baseline to 6 at 24 weeks (P < .001), while the DLQI improved from 4 to 3, respectively (P < .001). The median anagen-to-telogen ratio increased from 2.25 to 4.00 to 6.02 at weeks 0, 12, and 24, respectively. No significant adverse events were reported. This new topical active blend is effective in the treatment of AGA, with high degree of patients' satisfaction, improvement of quality of life, and an excellent safety profile. Thus, it may represent a useful alternative therapeutic approach for AGA.

Keywords: 5-alpha reductase; dihydroquercetin-glucoside; epigallocatechin gallate-glucoside; pattern hair loss; polyphenols; therapy; topical; trichogram.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Alopecia / diagnosis
  • Alopecia / drug therapy
  • Female
  • Hair*
  • Humans
  • Male
  • Quality of Life*
  • Treatment Outcome